CDX2 and colorectal carcinoma: We found that 20% of SBAs expressed the lower GI marker SATB2, while 6% of SBAs exhibited a complete CRC-like immunoprofile (i.e., CK7−/CK20+/CDX2+/SATB2+/AMACR+).